- Global Pharma News & Resources

aap receives further funding of up to EUR 2.7 million for its innovative antibacterial silver coating technology

DGAP-News: aap Implantate AG / Key word(s): Study/Financing
19.11.2019 / 07:20
The issuer is solely responsible for the content of this announcement.

aap Implantate AG ("aap") announces that its innovative antibacterial silver coating technology will be further funded by the German Federal Ministry of Education and Research ("BMBF"). aap can receive grants of up to around EUR 2.7 million for expenses incurred by carrying out the human clinical study for the intended market approval of its silver coating technology. In a first step, aap received a funding commitment of up to about EUR 0.7 million for the conception and qualification of the human clinical study.

Following the recent approval of the human clinical study by the Federal Institute for Drugs and Medical Devices ("BfArM"), aap now still needs the approval of the ethics commissions in view of the start of the study in Germany. Furthermore, the doctors participating in the study have already been trained in recent months and the equipment of the corresponding clinics with silver-coated implants has been prepared.

The benefit granted to the company (aap funding code 13GW0449A+B) is part of the BMBF's "Health Industry in the Health Research Framework Programme" field of action. According to the BMBF, funding will be provided for projects on the topic of "Transferring medical technology solutions into patient care - proving clinical evidence without delay". The funding programme aims to introduce small and medium-sized enterprises (SMEs) to changing legal and regulatory conditions and support them in the clinical validation of medical technology solutions. The aim is to promote the rapid transfer of innovations into healthcare and reduce the risk of late failure of investments in research and development. For further information, please refer to the corresponding guideline on the BMBF website: bekanntmachung-1376.html.

The further BMBF funding underlines again the innovative character of aap's silver coating technology and its potential to significantly reduce the cost burden on healthcare systems.


Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact:

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49/30/750 19 - 134; Fax: +49/30/750 19 - 290;

19.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
ISIN: DE0005066609
WKN: 506660
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 915667

End of News DGAP News Service

Editor Details

Last Updated: 19-Nov-2019